In the PARKIDENT clinical trial, strains were isolated from saliva samples of Parkinson's patients at baseline and during a follow-up visit. Strains were preanalyzed by multiplex PCR for serotype and collagen-binding proteins, followed by high-throughput sequencing and bioinformatics analysis using RAST and BLAST . Of 40 patients in the Parkident clinical trial, only 24 had Streptococcus mutans strains isolable from salivary swabs. Serotyping revealed that over 80% of the 44 strains isolated were serotype c, in line with prevalence data in the literature. Finally, the cbm gene was not found in any strain, and only 5 strains possessed the cnm gene, all of them serotype c. Trial registry: ClinicalTrials.gov ID NCT03827551, First submitted: 2019-01-25.
